1. Search Result
Search Result
Results for "

Escherichia coli gyrase

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

3

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0147
    Pefloxacin
    2 Publications Verification

    Pefloxacinium

    Antibiotic Bacterial Parasite DNA/RNA Synthesis Topoisomerase Infection Inflammation/Immunology
    Pefloxacin is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC50 of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC90s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .
    Pefloxacin
  • HY-B0147S

    Pefloxacinium-d5

    Antibiotic Bacterial Isotope-Labeled Compounds Others
    Pefloxacin-d5 is the deuterium labeled Pefloxacin (HY-B0147). Pefloxacin is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC50 of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC90s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies .
    Pefloxacin-d5
  • HY-117657

    Topoisomerase Bacterial Inflammation/Immunology Cancer
    (-)-BO 2367, an antimicrobial quinolone, is a strong mammalian and bacterial topoisomerase II inhibitor. (-)-BO 2367 shows IC50 values with 3.8 μM, 0.5 μM, and 1 μM against the DNA relaxation activity of L1210 topoisomerase II and the supercoiling activities of Escherichia coli gyrase and Micrococcus luteus gyrase, respectively. (-)-BO 2367 is a potent antitumor agent .
    (-)-BO 2367
  • HY-115990

    Topoisomerase Bacterial Infection
    Topoisomerase IV inhibitor 2 (compound 7d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.23 μM and 0.43 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .
    Topoisomerase IV inhibitor 1
  • HY-115991

    Topoisomerase Bacterial Infection
    Topoisomerase IV inhibitor 2 (compound 5d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.35 μM and 0.55 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 1.985 μM and 0.744 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .
    Topoisomerase IV inhibitor 2
  • HY-170567

    Topoisomerase Bacterial Antibiotic Infection
    DNA gyrase/Topo IV-IN-1 (Compound 27) is an inhibitor of DNA gyrase and topoisomerase IV, exhibiting antibacterial activity. For Escherichia coli and methicillin-resistant Staphylococcus aureus DNA gyrases, DNA gyrase/Topo IV-IN-1 has an IC50 of 11 and 17 nM respectively, and for topoisomerase IV of Escherichia coli and methicillin-resistant Staphylococcus aureus, the IC50 values are 83 and 21 nM respectively. DNA gyrase/Topo IV-IN-1 can be used for research in the field of anti-infection .
    DNA gyrase/Topo IV-IN-1
  • HY-147948

    DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-4 (compound 8p) is a potent DNA gyrase inhibitor, with an IC50 of 0.13 μM. DNA Gyrase-IN-4 shows excellent antibacterial activity against Staphylococcus aureus, Listeria monocytogenes, Salmonella and Escherichia coli, with MIC values of 0.05, 0.05, 0.05, and 8 μg/mL, respectively .
    DNA Gyrase-IN-4
  • HY-101967

    DNA/RNA Synthesis Bacterial Infection
    GSK 299423 is an antibiotic agent.GSK299423 shows potent inhibition of supercoiling by DNA gyrase from S. aureus(IC50=14 nM)and Escherichia coli(IC50=100 nM .
    GSK299423
  • HY-172962

    DNA/RNA Synthesis Bacterial Infection
    DNA Gyrase-IN-17 (Compound 5C) is a DNA Gyrase inhibitor. DNA Gyrase-IN-17 exhibits significant antibacterial activity against a variety of Gram-positive and Gram-negative strains (such as Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa, etc.), with a MIC value of 62.5 μg/mL. DNA Gyrase-IN-17 interferes with DNA replication by inhibiting bacterial DNA gyrase. DNA Gyrase-IN-17 can be used in the development of antibacterial drugs, especially for the study of drug-resistant strains .
    DNA Gyrase-IN-17
  • HY-14780

    NXL 101

    Antibiotic Topoisomerase DNA/RNA Synthesis Bacterial Infection
    Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and DNA gyrase. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L .
    Viquidacin
  • HY-B0395E

    (1S,2R,7S)-DU-6859a; DU-6856

    Antibiotic Bacterial Topoisomerase Infection
    (1S,2R,7S)-Sitafloxacin (DU-6856) is an enantiomer of Sitafloxacin (HY-B0395). (1S,2R,7S)-Sitafloxacin is a topoisomerase inhibitor. (1S,2R,7S)-Sitafloxacin is an antibiotic. (1S,2R,7S)-Sitafloxacin has inhibitory activity against Escherichia coli DNA gyrase (IC50 0.18 μg/mL) and Staphylococcus aureus topoisomerase IV. (1S,2R,7S)-Sitafloxacin has antibacterial activity and can be used in the study of various bacterial infections .
    (1S,2R,7S)-Sitafloxacin
  • HY-B0398
    Nalidixic acid
    2 Publications Verification

    Bacterial Antibiotic Topoisomerase Infection
    Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .
    Nalidixic acid
  • HY-B0398A
    Nalidixic acid sodium salt
    2 Publications Verification

    Bacterial Antibiotic Topoisomerase Infection
    Nalidixic acid sodium salt, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .
    Nalidixic acid sodium salt
  • HY-B0398AR

    Bacterial Antibiotic Topoisomerase Infection
    Liquiritin (Standard) is the analytical standard of Liquiritin. This product is intended for research and analytical applications. Liquiritin, a flavonoid isolated from Glycyrrhiza uralensis, is a potent and competitive AKR1C1 inhibitor with IC50s of 0.62 μM, 0.61 μM, and 3.72μM for AKR1C1, AKR1C2 and AKR1C3, respectively. Liquiritin efficiently inhibits progesterone metabolism mediated by AKR1C1 in vivo . Liquiritin acts as an antioxidant and has neuroprotective, anti-cancer and anti-inflammatory activity .
    Nalidixic acid (sodium salt) (Standard)
  • HY-B0398R

    Bacterial Antibiotic Topoisomerase Infection
    Nalidixic acid (Standard) is the analytical standard of Nalidixic acid. This product is intended for research and analytical applications. Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria .
    Nalidixic acid (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: